GlassScriptPhysician profile
Crystal M Newby
NPI 1871599290
$3,386.30
in general payments reported to CMS, 2019-2025
32 companies · $552 in 2025
The $552 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $292 · 2021: $505 · 2022: $1,013 · 2023: $409 · 2024: $354 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.82 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.40 | 2019-2025 | |
| Gynesonics, INC. | $523.99 | 2022 | |
| Astellas Pharma US INC | $294.08 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $171.64 | 2025 | |
| Organon LLC | $156.53 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $156.41 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $134.88 | 2023-2024 | Myfembree |
| Pfizer INC. | $113.52 | 2019-2024 | |
| Therapeuticsmd, INC. | $102.01 | 2019-2022 | |
| Medtronic, INC. | $98.31 | 2022-2024 | Truclear |
| Hologic Sales and Service, LLC | $97.61 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $97.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.05 | 2019-2025 | |
| Evofem Biosciences, INC. | $87.22 | 2021-2022 | |
| Agile Therapeutics, INC. | $79.59 | 2021-2024 | Twirla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $79.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $61.09 | 2021-2022 | |
| Exeltis, USA INC. | $60.03 | 2021-2022 | |
| Millicent US INC | $56.93 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Avion Pharmaceuticals | $52.55 | 2020-2021 | |
| Biogen, INC. | $43.11 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $31.94 | 2021-2022 | |
| Baxter Healthcare | $31.10 | 2025 | Perclot |
| Amag Pharmaceuticals, INC. | $30.48 | 2019 | |
| Lupin INC. | $23.82 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.61 | 2021 | |
| Urovant Sciences INC | $16.16 | 2022 | |
| Aesculap, INC. | $15.21 | 2019 | |
| Ethicon US, LLC | $14.61 | 2019 | |
| Coopersurgical, INC. | $13.53 | 2020 | |
| Minerva Surgical, INC | $13.27 | 2019 | |
| Agiliti Surgical, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Newby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.